COMPARATIVE ANALYSIS OF THE TREATMENT OF BURNING MOUTH SYNDROME AND SECONDARY MOUTH BURNING WITH LOW INTENSITY LASER THERAPY AND TRANSNCUTANEOUS ELECTRIC NERVE STIMULATION: A RANDOMIZED CLINICAL TRIALS
Burning Mouth Syndrome. Xerostomia. Dysgeusia. Low-Level Light Therapy. Transcutaneous Electric Nerve Stimulation
Introduction: Burning Mouth Syndrome (BMS) is a condition that manifests as a burning sensation in the oral mucosa of patients who do not have local or underlying systemic factors. The SAB makes a differential diagnosis with Secondary Mouth Burning (SMB), which is characterized by the same burning sensation in the mouth, however, with the occurrence of local or systemic changes that trigger such symptoms. Objective: to compare the effect of low-intensity laser and transcutaneous electrical nerve stimulation in the treatment of BMS and SMB. Methodology: Randomized clinical trial in which the sample will consist of 20 participants with SAB and 20 participants with ABS, which will be subdivided into two groups according to the therapy used. If the sample has a normal distribution, the Analysis of Variance (ANOVA) test will be performed for repeated measures, otherwise, the Friedman's non-parametric test will be performed to check if there is a statistically significant difference in the BMS and SMB group regarding the type of therapy employed. Partial Results: The study's partial sample consisted of 23 participants, most of them female (20 cases) in post-menopause (85%). The average age of participants was 58 years for the BMS group and 63,44 years for the SMB group. In total, 7 participants were diagnosed with BMS and 16 participants with SMB. Most participants with BMS and SMB had severe symptoms before starting treatment (T0). Only one participant from the BMS group and five from the SMB group reported xerostomia at T0. Regarding the unstimulated salivary flow collected in the same period of time, it was found that only one participant in each condition presented hyposalivation. Additionally, the mean salivary pH at T0 for the BMS group was 7.0 and for the SMB group it was 6.9 and only one case of dysgeusia was observed in the SMB group before starting treatment.